Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important ones are Ulcerative colitis (UC), with inflammation localized mostly in the colon, and Crohn’s disease (CD) which affects the entire gastrointestinal tract. The highest reported prevalence of IBD is in Europe (UC, 505 per 100,000 persons; CD, 322 per 100,000 persons) and North America (UC, 249 per 100,000 persons; CD, 319 per 100,000 persons) and affects people of all ethnicities.
Given the high prevalence of gastrointestinal disease, the value of calprotectin in IBD patient diagnosis, and the downfalls of traditional treatment pathways it is clear that calprotectin testing is beneficial to patient care.
In this webinar, Dr. Arne Roseth shares in-depth knowledge on calprotectin and its utility in a clinical laboratory setting as well as his experiences with utilizing this biomarker in primary care.
- Background information on calprotectin including the history and how it is has evolved as a biomarker
- Technical details of calprotectin testing in the laboratory
- Perspectives and experience on the use of the calprotectin in primary care
Please Join BUHLMANN and Meridian for this interesting presentation. Watch the recording today!
About the Presenter
Dr. Arne Roseth
Dr. Arne Roseth is a US-Norwegian gastroenterologist with more than 25 years of practical experience in the use of calprotectin and one of the global key opinion leaders for the application of this novel biomarker. He produced the very first study and publication on calprotectin and has numerous publications to date. Currently, Dr. Roseth is a gastroenterologist at Lovisenberg Hospital, Oslo in Norway and continues to be an excellent resource on this topic.